tpst-1495
tpst-1495: sourced relationships with 1 company · 1 clinical trial tracked.
tpst-1495 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could tpst-1495 → TPST affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Tempest Therapeutics, Inc. (TPST) | Phase 1 |
Clinical Trial Registry Records (1)
Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Primary endpoint: Determination of maximum tolerated dose and/or recommended Phase 2 dose (RP2D) and optimum dose schedule for TPST-1495 as a single agent and in combination with pembrolizumab
Frequently asked questions
Which companies have sourced relationships with tpst-1495?
tpst-1495 has dated SEC/FDA relationship records for Tempest Therapeutics, Inc..
How many clinical trials involve tpst-1495?
BioSniper tracks 1 clinical trial involving tpst-1495.